Novo Nordisk A/S (ETR:NOV)
41.44
+0.41 (1.00%)
At close: Dec 5, 2025
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
€537,940
Profits / Employee
€176,879
Market Cap
184.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Merck KGaA | 59,020 |
| Siemens Healthineers AG | 73,840 |
| Bayer Aktiengesellschaft | 91,864 |
| Fresenius SE & Co. KGaA | 176,486 |
| Sartorius Aktiengesellschaft | 13,528 |
| Fresenius Medical Care AG | 111,513 |
| Carl Zeiss Meditec AG | 5,730 |
| Fielmann Group AG | 24,363 |
Novo Nordisk News
- 16 hours ago - This Pharmaceutical Giant Fell by 10% After a Setback: Time to Sell the Stock? - The Motley Fool
- 22 hours ago - India's Healthify eyes more weight-loss drugmaker tie-ups after Novo Nordisk pact - Reuters
- 1 day ago - Wegovy's prices are going down, but they are ‘wildly different' — and confusing - Market Watch
- 2 days ago - Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment - Reuters
- 2 days ago - Details of failed studies cast pall on Novo Nordisk's GLP-1 as Alzheimer's treatment - Reuters
- 2 days ago - Novo Nordisk gears up for December Ozempic launch in India, sources say - Reuters
- 2 days ago - Medicare Just Cut the Price of Wegovy: Should You Sell Novo Nordisk Stock? - The Motley Fool
- 3 days ago - Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials - Reuters